The combination of a long-acting delivery 
. This approach could become the method ofchoice for the endocrine treatment of advanced prostate carcinoma. Nevertheless, it is possible that the therapeutic response could be improved by combining LH-RH agonists with other compounds including peptides such as somatostatin analogs (3) or various chemotherapeutic agents (4, 5) .
Among the major actions of somatostatin is the inhibition of the release of the pituitary growth hormone (GH) and, under certain conditions, of prolactin (6) . Prolactin has been shown to stimulate prostate growth, to enhance metabolic processes in the prostate, and to potentiate the response of the prostate to 5-dihydrotestosterone (7) (8) (9) (10) (11) (12) (13) . Consequently, prolactin could be involved in prostate cancer as a cofactor (7) (8) (9) (10) (11) (12) (13) (14) . The reduction in prolactin levels produced by the administration of a somatostatin analog, combined with the decrease in serum testosterone that results from chronic treatment with LH-RH agonists, may inhibit growth of prostate tumors better than LH-RH agonists alone (14) . The fall in GH levels induced by somatostatin analogs could, through mechanisms involving endogenous growth factors, be even more important for the inhibition of tumor growth (14) than the reduction in prolactin. GH stimulates cell differentiation directly and clonal expansion indirectly through local production of insulin-like growth factor I (15) (16) (17) (18) .
A family of insulin-like growth factor polypeptides, also called somatomedins, and other growth factors including epidermal growth factor (EGF), platelet-derived growth factor, fibroblast growth factor, and transforming growth factor appear to be involved in the proliferation of both normal and neoplastic cells (19) (20) (21) (22) (23) . In addition, transforming growth factor, platelet-derived growth factor, and other growth factors are implicated in phenotypic transformation of cells (24) . There are also growth inhibitors that have antiproliferative effects on cells (25) (26) (27) (28) . One of these endogenous growth inhibitors is somatostatin (13, 14, 28) , which blocks the release or action of many hormones (6) . Somatostatin inhibits numerous cellular processes (13) and nullifies the cell replication induced by EGF (28) . In the MIA PaCa-2 human pancreatic cancer cell line, somatostatin reverses the stimulatory effect of EGF on the phosphorylation of the tyrosine kinase portion of the EGF receptor (29 (30) . In the first experiment the treatment was initiated 45 days after transplantation and in the second study, the treatment was initiated 4 months after transplantation, when the tumor volume was-1500 mm3.
Peptides. Analogs D-Phe-Cys-Tyr-D-Trp-Lys-Val-CysThr-NH2 (RC-121) and D-Phe-Cys-Tyr-D-Trp-Lys-Val-CysTrp-NH2 (RC-160) were synthesized by solid-phase methods and repurified by HPLC (3). Both analogs were 100-150 times more potent than somatostatin on inhibition of GH release (3, 13, 14 After 70-83 days of treatment, the rats were sacrificed by decapitation. Trunk blood was collected, and serum was separated. Tumors and various organs were removed, cleaned, weighed, and then frozen on dry ice. Serum levels of testosterone, luteinizing hormone, GH, and prolactin were measured by RIAs as described (1, 5) . All data are expressed as the mean ± SEM. Statistical analyses were performed by using a computer-assisted program and Duncan's new multiple-range test (32) (Tables 3 and 4 ). In the groups that received somatostatin analog RC-121 b.i.d. or microcapsules of RC-160 every 2 weeks, serum GH levels were significantly depressed as compared with controls and were lowest in groups given the combination treatment. The pharmacokinetics of the liberation of the analog RC-160 from prototype-7 microcapsules were investigated in normal rats. Measurements of serum levels of RC-160 by specific RIA revealed that significantly elevated levels of this analog persisted for at least 2 weeks after the injection of the microcapsules. The levels of RC-160 reached a peak of 27 ng/day on the day after the injection but then declined to 1-2 ng/ml between days 5 and 15. (M. Mason-Garcia, T.W.R., and A.V.S., unpublished results).
DISCUSSION
In the studies described here, we investigated a possible synergistic inhibitory effect that could result from combining a modern hormonal therapy based on LH-RH agonist (1, 2) with the administration of potent somatostatin analogs on the growth of hormone-dependent Dunning R-3327H prostatic adenocarcinoma in rats. The suppression of pituitary and gonadal functions that occurs after chronic administration of LH-RH agonists produces a state of chemical castration and provides the current approach for the treatment of prostate cancer and other sex hormone-dependent tumors (1, 2, 4, 5, 33 (4, 5, 33, 35) . One of the approaches for improving the therapeutic response and its duration could be based on combining hormonal therapy with chemotherapy (4, 5, 36) . The combination of LH-RH agoinsts with somatostatin analogs might also result in an increase in the therapeutic response in prostate cancer and possibly in other neoplasms (14) . This view is based on the finding that somatostatin and its analogs, in addition to suppressing GH and prolactin (3, 6, 14, 37) , appear to directly inhibit the action of endogenous growth factors such as EGF by mechanisms involving interference with signal transmission (13, 28, 29) . Prolactin may be a cofactor in prostate cancer (7) (8) (9) (10) (11) (12) (13) (14) and breast cancer (14) , and GH promotes various growth factors that may be involved in proliferation and transformation of malignant cells (15-18, 21, 23) . Thus somatostatin analogs might inhibit prostate and breast cancers by interfering with the secretion of GH and prolactin and with the action of endogenous growth factors. Somatostatin also suppresses the release of pancreatic and gut hormones and exocrine secretions of the pancreas and stomach (6, 13) and consequently its analogs could be of value for impeding the growth of other cancers, such as pancreatic cancer (13, 14, 29, 31) . In addition, the secretion of bombesin and the related peptide gastrin releasing peptide, which are growth factors for small cell lung carcinomas (38) (39) (40) , might be reduced by somatostatin. Another possible mechanism by which somatostatin analogs might inhibit tumor growth is the interference with the synthesis of autocrine growth factors by tumor cells.
Somatostatin analogs could also inhibit oncogene products, several of which are similar to growth factors or their receptors (41) (42) (43) . Growth factors or aberrant receptors generated by the oncogenes (20) could be responsible for promoting tumor cell growth (44) . Activated oncogenes and EGF receptors have been found in the human bladder and lung cancer cell lines (19, 20) . Regardless of the exact mechanisms of action, several of which are possible, somatostatin analogs, by virtue of their antiproliferative properties, can probably be used for manipulations aimed at the inhibition of the processes of malignant growth (13) .
The present results demonstrate the effectiveness of hormonal treatment based on microcapsules of [D-Trp6]LH-RH combined with somatostatin analogs in suppressing the growth of Dunning R-3327H prostate tumors in rats. It is possible that somatostatin analogs could be developed for use as adjuncts to LH-RH agonists in the treatment of prostate cancer in humans, but additional experimental studies and clinical trials are necessary to establish the usefulness of such therapy.
Note Added in Proof. Estimation by RIA of the levels of somatomedin-C/insulin-like growth factor 1 in serum of rats bearing Dunning R-3327H prostate tumors indicates that this growth factor is decreased after chronic treatment with somatostatin analogs. Levels of somatomedin-C in extracted serum of rats treated for 84 days with the somatostatin analog RC-160 alone or in combination with [D-Trp6]LH-RH, were significantly reduced as compared to controls (V. Csernus, T.W.R., and A.V.S., unpublished results). 
